SCHEMBL4746430

SCHEMBL4746430

Cc1cn(C)c(=O)c2c(OCc3ccccc3)c3n(c12)CCN(Cc1ccc(F)cc1)C3=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.46
LMNA P02545 7/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
NCOA3 Q9Y6Q9 1/20 0.46
HTT P42858 6/20 0.42
TDP1 Q9NUW8 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
KCNH2 Q12809 2/20 0.41
GRM2 Q14416 2/20 0.41
ALDH1A1 P00352 5/20 0.41
NPSR1 Q6W5P4 2/20 0.38
PKM P14618 1/20 0.38
TSHR P16473 2/20 0.37
USP2 O75604 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4749017 0.82 KCNH2 (0.44) LMNAHTTMEN1KMT2AKCNH2
SCHEMBL16185259 0.81 GRM2 (0.36) SMN1; SMN2LMNAL3MBTL1NCOA3HTT
SCHEMBL5532677 0.79 SMN1; SMN2 (0.51) SMN1; SMN2LMNAL3MBTL1NCOA3HTT
SCHEMBL4141251 0.78 SMN1; SMN2 (0.49) SMN1; SMN2LMNAL3MBTL1NCOA3HTT
SCHEMBL3981450 0.77 SMN1; SMN2 (0.43) SMN1; SMN2LMNAL3MBTL1NCOA3HTT
SCHEMBL4746270 0.75 SCD (0.40) SMN1; SMN2HTTMEN1KMT2AALDH1A1
SCHEMBL4744811 0.75 KCNH2 (0.40) SMN1; SMN2LMNAL3MBTL1NCOA3HTT
SCHEMBL3985585 0.74 LMNA (0.44) SMN1; SMN2LMNAL3MBTL1NCOA3HTT
SCHEMBL3989708 0.74 SMN1; SMN2 (0.40) SMN1; SMN2LMNAL3MBTL1NCOA3HTT
SCHEMBL3987185 0.74 SMN1; SMN2 (0.40) SMN1; SMN2LMNAL3MBTL1NCOA3HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1677599-A4 HYDROXY PYRIDOPYRROLOPYRAZINE DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2008-10-22 EP disclosed
US-7435735-B2 Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2008-10-14 US disclosed
US-7435735-B2 Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2008-10-14 US disclosed
US-7435735-B2 Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2008-10-14 US disclosed
US-20070093496-A1 Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-04-26 US disclosed
US-20070093496-A1 Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-04-26 US disclosed
US-20070093496-A1 Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-04-26 US disclosed
EP-1677599-A1 HYDROXY PYRIDOPYRROLOPYRAZINE DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-07-12 EP disclosed
WO-2005041664-A1 HYDROXY PYRIDOPYRROLOPYRAZINE DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093496-A1 Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors DHPS, DPYD, TYMP SMN1; SMN2 3773/4885LMNA 2784/4885L3MBTL1 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.